Comments on: Life sciences briefing: Tuesday, Aug. 21, 2007 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/ News About Tech, Money and Innovation Tue, 24 Nov 2009 03:52:54 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: Stealthy device maker ExploraMed raises $18.5M » VentureBeat http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-806652 Stealthy device maker ExploraMed raises $18.5M » VentureBeat Tue, 29 Apr 2008 15:51:37 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-806652 [...] of which we’ve covered here at VentureBeat LifeScience. Its most recent companies include Vibrynt, a stealthy device maker that raised $16 million in Aug. 2007, and NeoTract, a Pleasanton, Calif., developer of devices for non-cancerous prostate [...] [...] of which we’ve covered here at VentureBeat LifeScience. Its most recent companies include Vibrynt, a stealthy device maker that raised $16 million in Aug. 2007, and NeoTract, a Pleasanton, Calif., developer of devices for non-cancerous prostate [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Jan. 9, 2008 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-770324 VentureBeat » Life sciences briefing: Wednesday, Jan. 9, 2008 Sat, 02 Feb 2008 20:04:34 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-770324 [...] and is developing a similar system for prostate cancer. We previously covered the company here. For more stories on VentureBeat Life Sciences, click here.Tagged co:Confirma, inv:Fluke Venture [...] [...] and is developing a similar system for prostate cancer. We previously covered the company here. For more stories on VentureBeat Life Sciences, click here.Tagged co:Confirma, inv:Fluke Venture [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Jan. 23, 2008 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-749184 VentureBeat » Life sciences briefing: Wednesday, Jan. 23, 2008 Thu, 24 Jan 2008 00:57:10 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-749184 [...] deficit of $72 million since its formation in 1989. See our previous coverage of the company here (third item). For more stories on VentureBeat Life Sciences, click here.Tagged amyotrophic lateral [...] [...] deficit of $72 million since its formation in 1989. See our previous coverage of the company here (third item). For more stories on VentureBeat Life Sciences, click here.Tagged amyotrophic lateral [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Nov. 7, 2007 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-621210 VentureBeat » Life sciences briefing: Wednesday, Nov. 7, 2007 Wed, 07 Nov 2007 22:06:41 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-621210 [...] maximum take from the offering to $92 million from $127 million. (See our earlier coverage here and here.) The company priced the offering at $8 a share, although investors pushed up the price 55 cents, [...] [...] maximum take from the offering to $92 million from $127 million. (See our earlier coverage here and here.) The company priced the offering at $8 a share, although investors pushed up the price 55 cents, [...]

]]> By: VentureBeat » Life sciences briefing: Monday, Oct. 22, 2007 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-591446 VentureBeat » Life sciences briefing: Monday, Oct. 22, 2007 Tue, 23 Oct 2007 01:19:55 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-591446 [...] of a medical-device company than one focused on “medical aesthetics,” in the first item here. The company’s main customers are plastic surgeons and [...] [...] of a medical-device company than one focused on “medical aesthetics,” in the first item here. The company’s main customers are plastic surgeons and [...]

]]> By: VentureBeat » Life sciences briefing: Monday, Sept. 24, 2007 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-555620 VentureBeat » Life sciences briefing: Monday, Sept. 24, 2007 Fri, 28 Sep 2007 12:51:52 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-555620 [...] can find our earlier coverage of Adnexus, which filed for its IPO just last month, here and here. Alantos is the second biotech I’m aware of that’s recent chosen an [...] [...] can find our earlier coverage of Adnexus, which filed for its IPO just last month, here and here. Alantos is the second biotech I’m aware of that’s recent chosen an [...]

]]> By: David P. Hamilton http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-492340 David P. Hamilton Wed, 22 Aug 2007 21:23:06 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-492340 That's certainly plausible, but I tend to think they're actually headed in the other direction. This is from the summary section of BioForm's S-1: <blockquote>Our strategy is to become a worldwide leader in medical aesthetics by building on our success with Radiesse, gaining a market leading position in dermal fillers, enhancing the strength of our sales and marketing organizations in the United States and Europe and commercializing new products beyond dermal fillers that enhance the practice of medical aesthetics.</blockquote> That’s certainly plausible, but I tend to think they’re actually headed in the other direction. This is from the summary section of BioForm’s S-1:

Our strategy is to become a worldwide leader in medical aesthetics by building on our success with Radiesse, gaining a market leading position in dermal fillers, enhancing the strength of our sales and marketing organizations in the United States and Europe and commercializing new products beyond dermal fillers that enhance the practice of medical aesthetics.

]]> By: DV Henkel-Wallace http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-491962 DV Henkel-Wallace Wed, 22 Aug 2007 18:58:50 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-491962 Actually, you could interpret bioform's filing the other way around. That is, they'd like to be more "medical" and might be making efforts in that way (haven't read the S-1). But if the reality is that all their revenue is esthetic, they pretty much have to describe themselves that way for the SEC's benefit. Actually, you could interpret bioform’s filing the other way around. That is, they’d like to be more “medical” and might be making efforts in that way (haven’t read the S-1). But if the reality is that all their revenue is esthetic, they pretty much have to describe themselves that way for the SEC’s benefit.

]]> By: VentureBeat » Wrinkle treater BioForm Medical files for $115M IPO http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/comment-page-1/#comment-489512 VentureBeat » Wrinkle treater BioForm Medical files for $115M IPO Tue, 21 Aug 2007 22:25:08 +0000 http://venturebeat.com/2007/08/21/life-science-briefing-tuesday-aug-21-2007/#comment-489512 [...] and other products for cosmetic procedures, filed to raise $115 million in an initial offering. See our story in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...] [...] and other products for cosmetic procedures, filed to raise $115 million in an initial offering. See our story in today’s daily briefing at VentureBeat Life Sciences. Tagged N/A VentureBeat [...]

]]>